The Filing Desk

Evolus

EOLS · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

EOLS · Last close · November 13, 2026
$6.96
Value Evolus yourself

Evolus' revenue rose 11.6% to $297 million in fiscal 2025. Its operating margin was −11.0%, up from −12.9% a year earlier. Free cash flow was −$46 million. The diluted share count rose 4.0%.

EVOLUS, INC. Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0001628280-26-014001 Updated
Revenue
$297M
11.6%
Operating margin
−11.0%
1.9 pts
Net income
−$52M
 
Free cash flow
−$46M
 
Return on capital
−47.2%
23.4 pts
Market cap
$460M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Evolus does

Evolus sells aesthetic products that people pay for out of pocket, not through insurance. Its customers are licensed aesthetic practitioners, who inject its products. It focuses on two large categories of cosmetic injectables: neurotoxins and hyaluronic acid gels.

Its first product, Jeuveau, is a botulinum toxin type A product that temporarily improves the look of moderate to severe frown lines between the eyebrows in adults. It positions it as an alternative to BOTOX. Jeuveau is sold in the United States, Canada, certain European markets and Australia. Its second line, Evolysse, is a set of injectable hyaluronic acid gels for wrinkles and folds. The FDA approved the first two in February 2025, and they launched in the U.S. in April 2025. Evolus expects to launch all four in Europe in the second quarter of 2026 and to add two more in the U.S.

Evolus uses programs such as a consumer loyalty program, co-branded marketing and promotions to win customers. It depends on Symatese for approval of Evolysse in the United States.

Its biggest risks, as it describes them

  • It has lost money since it started and may keep losing money.
  • Its products face tough competition and may not win enough use by practitioners or demand from consumers.
  • Its sales depend on consumer discretionary spending, and on tariffs and other trade changes.
  • It relies on Symatese to win and keep U.S. approval for the Evolysse line.
  • It may need more financing, and must follow a settlement agreement with Medytox.
From Evolus's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Evolus lost money in fiscal 2025: a net loss of $52 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments14654638754
Debt incl. finance leases7172120122146
Net debt (negative means net cash)−7518583492
Net debt to EBITDA—————
Debt to equity0.9x3.9x———
Interest coverage−31.8x−7.2x−3.6x−1.8x−1.7x
Current ratio3.1x2.2x2.3x2.4x1.9x
Quick ratio3.1x1.8x2.1x2.2x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Evolus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Evolus reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 96 of 92 of 9
Rule of 4018.9%24.4%−3.8%
Altman Z''−9.27−7.02−8.65
Accruals ratio−15.1%−15.4%−4.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsPassPassFail
F-score4 of 96 of 92 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Evolus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
EvolusFY2511.6%−11.0%−15.4%−47.2%—2
Ironwood PharmaceuticalsFY25−15.7%33.3%42.9%———Compare
Rigel PharmaceuticalsFY2564.2%42.6%—91.3%−0.8x7Compare
Xeris BiopharmaFY2543.7%8.5%—19.6%4.2x7Compare
CorMedixFY25617.0%48.2%55.4%—−0.9x—Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—03556100149202266297
Revenue growth———61.9%76.3%49.1%36.0%31.8%11.6%
Gross profit—027385690138182197
Research and development7642257910
Operating income−12−46−99−153−44−65−49−34−33
Net income−4−47−90−163−47−74−62−50−52
Diluted EPS (US$)−0.27−1.92−3.19−4.83−0.94−1.33−1.08−0.81−0.80
Diluted shares (millions)162428345056576264
Cash flow
Cash from operations−13−26−93−58−33−85−34−18−42
Capital expenditure000102023
Free cash flow−13−26−94−59−34−87−34−19−46
Dividends paid000000000
Share buybacks000000000
Acquisitions000000000
Stock-based compensation1710111011162221
Balance sheet at fiscal year end
Cash and short-term investments09313010814654638754
Debt incl. finance leases139074407172120122146
Total assets152172240209258178189233226
Total liabilities22888161282176160210227249
Shareholders' equity−768480−738218−216−23
Margins and ratios
Gross margin——77.0%67.6%56.3%60.4%68.1%68.5%66.3%
Operating margin——−283.3%−270.7%−44.5%−44.0%−24.4%−12.9%−11.0%
Net margin——−257.8%−288.3%−47.0%−50.1%−30.5%−18.9%−17.4%
Free cash flow margin——−268.4%−103.8%−33.9%−58.2%−17.1%−7.3%−15.4%
Rule of 40 (growth + FCF margin)———−41.9%42.4%−9.1%18.9%24.4%−3.8%
Return on capital—−134.1%————−106.1%−70.7%−47.2%
Return on equity——−109.9%——−148.3%———
Return on assets—−28.9%−43.7%−72.5%−20.1%−34.2%−33.6%−23.9%−22.5%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Evolus' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Evolus.